Meeting
Abstract Number: 484
SHM Converge 2021
Case Presentation: A 78 year old man with recurrent metastatic adenosquamous lung carcinoma (recently initiated pembrolizumab), CAD s/p CABG, HTN, DM2, and HLD, presented with 2 weeks of fatigue, myalgias, anorexia, and weakness acutely worsening in the prior 2 days. He had no fever, chills, chest pain, dyspnea, orthopnea, palpitations, or lower extremity edema. ED […]
Abstract Number: 485
SHM Converge 2021
Case Presentation: Immunotherapy is an emerging therapeutic option in the field of oncology. Dermatological toxicities are the most prevalent immune-related adverse events associated with immunotherapy. Herein, we report a case of a 60-year-old male who developed localized bullous pemphigoid after nearly a year of treatment with a PD-1 inhibitor, nivolumab, for metastatic renal cell carcinoma. […]